Apotex Health Corp has seen notable price movement this week, reflecting its recent corporate developments and market sentiment.
This week, Apotex Health Corp (APTX.TO) experienced positive price action, closing at C$37.70, with a 1-day increase of 0.82% and a significant weekly rise of 11.93%. This performance is due to a mix of recent corporate developments and ongoing market dynamics.
Advertisement
Apotex Health Corp
APTX.TO
APTX.TO
Apotex Health Corp
WealthAwesomeAdvertisement
Market cap
$8.16B
P/E
21.8x
52W high
$40.18
52W low
$26.05
1W change
-5.20%
Analyst Price Targets
Based on analyst covering APTX
Wall Street analysts forecast APTX stock price to rise 16.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.24
+16.0% Upside
Current Price
C$35.55
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APTX's historical volatility
30-Day Vol
49.0%
Annualized
90-Day Vol
51.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$42.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$37.73 | C$31.86 – C$44.69 |
| 60 trading days | C$40.04 | C$31.52 – C$50.87 |
| 90 trading days | C$42.50 | C$31.70 – C$56.97 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors may find Apotex Health Corp's recent stock performance encouraging, especially with its strategic initiatives and analyst coverage indicating a bullish outlook. However, it’s important to consider market volatility and the company's fundamentals.
Apotex Health Corp's Stock Rises 11.93% This Week
With a market cap of approximately C$8.81 billion and a trailing P/E of 23.03, Apotex Health Corp is positioned in a competitive sector but must navigate market challenges ahead.
Bull case
The company’s recent strategic moves, such as integrating Cumberland Pharmaceuticals' U.S. branded businesses and receiving Health Canada approval for SEVMIA™, position Apotex for growth in the competitive generic drug market. Additionally, positive analyst sentiment, including a 'Buy' rating from Stifel, supports a bullish outlook.
Bear case
Despite the recent gains, potential investors should be cautious of market fluctuations and the company’s current P/E ratio of 23.03, which may suggest overvaluation relative to earnings. Furthermore, the absence of major news this week could create uncertainty in the stock's short-term performance.
Recent Price Action
Advertisement
Apotex Health Corp's stock closed at C$37.70, reflecting a 1-day increase of 0.82% and a remarkable weekly gain of 11.93%. This positive movement highlights investor confidence in the company's strategic initiatives and market positioning.
Company News and Developments
While there was no major company news this week, Apotex has recently made headlines for its strategic integration of Cumberland Pharmaceuticals' U.S. branded businesses and receiving approval for SEVMIA™, a generic semaglutide for chronic weight management. These developments are expected to enhance the company's market presence and product offerings.
Technical Picture
From a technical perspective, Apotex Health Corp is currently trading well above its 50-day and 200-day moving averages, both at C$31.80, indicating a bullish trend. The stock's 52-week range is between C$26.05 and C$38.93, with the current price sitting at approximately 90% of this range. The recent trading volume of 272,330 shares is below the 20-day average of 412,382 shares, suggesting a potential decrease in trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
